Chinese Equities Look to Benefit as China-s Slowing Economy Begins to Show Signs of Improvement

The Paragon Report Provides Stock Research on China Digital TV and Giant Interactive Group

Continue Reading

Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry-s Success in 2012

Five Star Equities Provides Stock Research on Array Biopharma and Sunesis Pharmaceuticals

Continue Reading

High Dividend Paying Companies Losing Luster Among Investors as Dividend Tax Rate Set to Increase

Five Star Equities Provides Stock Research on Frontier Communications and Windstream

Continue Reading

Improving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry-s Success in 2012

Five Star Equities Provides Stock Research on Alexza Pharmaceuticals and EntreMed

Continue Reading

Chinese Equities Receive a Boost as Manufacturing in China Rises for the First Time in 13 Months

The Paragon Report Provides Stock Research on Cleantech Solutions International and Zhongpin

Continue Reading

Consumer Spending Could Drop by as Much as $200 Billion if Upcoming “Fiscal Cliff” Is Not Avoided

The Paragon Report Provides Stock Research on The Coca-Cola and Mondelez International

Continue Reading

China to Provide Subsidies to Rare Earth Producers in Attempts to Boost Struggling Industry

Five Star Equities Provides Stock Research on Lynas and Quest Rare Minerals

Continue Reading

Demand for Rare Earths Expected to Top 200,000 Tons by 2020 — Molycorp Shares Surge as Executives Purchase Shares

Five Star Equities Provides Stock Research on Molycorp and Rare Element Resources

Continue Reading

Biotech Industry Skyrockets in 2012 as FDA New Drug Approval Rate Increases

Five Star Equities Provides Stock Research on Cytokinetics and Galectin Therapeutics

Continue Reading

FDA on Pace to Approve More New Drugs in 2012 Than the 30 Approved in 2011

Five Star Equities Provides Stock Research on CytRx and ZIOPHARM Oncology

Continue Reading